Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation

Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation

Abstract Mesenchymal‐epithelial transition (MET) pathway activation is associated with the mechanisms that influence properties affecting cancer cell survival and invasiveness. The MET exon 14 skipping mutation (METex14del) is found in 2%–3% of patients with non‐small cell lung cancer (NSCLC). Previ...

Full description

Bibliographic Details
Main Authors: Shinkichi Takamori, Taichi Matsubara, Takatoshi Fujishita, Kensaku Ito, Ryo Toyozawa, Takashi Seto, Masafumi Yamaguchi, Tatsuro Okamoto
Format: Article
Language:English
Published: Wiley 2021-03-01
Series:Thoracic Cancer
Subjects:
brain astasis
MET
met
non‐small cell lung cancer
tepotinib
Online Access:https://doi.org/10.1111/1759-7714.13871

Internet

https://doi.org/10.1111/1759-7714.13871

Similar Items